Concert Pharmaceuticals Plans To Move Diabetic Nephropathy Candidate Into Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech hopes proof-of-concept data will attract a development partner for CTP-499 against CKD.